Program
HSK50042
A development code. Also written as “HSK50042 dose 1”, “HSK50042 dose 2” and “HSK50042 dose 3”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Haisco Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haisco Pharmaceutical Group | 11 open or running | phase 2since Jul 22, 2026 | Jul 22, 2026 | Apr 10, 2028phase 2 · NCT07728721 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 22, 2026First study: phase 2 study in Idiopathic Pulmonary FibrosisFirst studyNCT07728721 · 175 planned
Ahead
- Apr 10, 2028Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07728721
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07728721Idiopathic Pulmonary Fibrosis | 2 | Not yet recruiting | Apr 10, 2028 | 175 |
How it is read
Names in the registry
- “HSK50042 dose 1”, 1 entry
- “HSK50042 dose 2”, 1 entry
- “HSK50042 dose 3”, 1 entry
Codes read as this program: HSK50042.
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.